Rigel Pharmaceuticals (RIGL) Total Non-Current Liabilities (2010 - 2025)
Rigel Pharmaceuticals' quarterly Total Non-Current Liabilities came in at $122.1 million in Q4 2025, up 1.17% year-on-year from $120.7 million in Q4 2024, and down 19.88% quarter-over-quarter from $152.4 million in Q1 2025.
Rigel Pharmaceuticals has reported Total Non-Current Liabilities for 16 years, with the latest figure at $122.1 million in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities rose 1.17% year-over-year to $122.1 million; the trailing twelve-month figure through Dec 2025 stood at $122.1 million (up 1.17% YoY), and the FY2025 full-year result was $122.1 million, up 1.17% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $122.1 million, down from $152.4 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $152.4 million in Q1 2025, with the low at $80.2 million in Q1 2021.
- Average Total Non-Current Liabilities over 5 years is $103.8 million, with a median of $105.7 million recorded in 2022.
- Year-over-year, Total Non-Current Liabilities soared 33.91% in 2021 and declined 0.55% in 2022.
- Tracing RIGL's Total Non-Current Liabilities over 5 years: stood at $84.2 million in 2021, then gained by 25.41% to $105.6 million in 2022, then grew by 0.28% to $105.9 million in 2023, then climbed by 13.96% to $120.7 million in 2024, then climbed by 1.17% to $122.1 million in 2025.
- The last three Total Non-Current Liabilities figures came in at $122.1 million (Q4 2025), $152.4 million (Q1 2025), and $120.7 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 122.11 Mn |
| Mar 31, 2025 | 152.41 Mn |
| Dec 31, 2024 | 120.71 Mn |
| Sep 30, 2024 | 114.07 Mn |
| Jun 30, 2024 | 118.34 Mn |
| Mar 31, 2024 | 118.21 Mn |
| Dec 31, 2023 | 105.93 Mn |
| Sep 30, 2023 | 108.40 Mn |
| Jun 30, 2023 | 104.23 Mn |
| Mar 31, 2023 | 105.80 Mn |
| Dec 31, 2022 | 105.63 Mn |
| Sep 30, 2022 | 86.73 Mn |
| Jun 30, 2022 | 84.79 Mn |
| Mar 31, 2022 | 89.07 Mn |
| Dec 31, 2021 | 84.23 Mn |
| Sep 30, 2021 | 82.48 Mn |
| Jun 30, 2021 | 85.26 Mn |
| Mar 31, 2021 | 80.16 Mn |
| Dec 31, 2020 | 71.31 Mn |
| Sep 30, 2020 | 67.10 Mn |
| Jun 30, 2020 | 69.83 Mn |
| Mar 31, 2020 | 59.86 Mn |
| Dec 31, 2019 | 88.66 Mn |
| Jun 30, 2018 | 17.61 Mn |
| Mar 31, 2018 | 18.97 Mn |
| Dec 31, 2017 | 18.43 Mn |
| Sep 30, 2017 | 15.01 Mn |
| Dec 31, 2016 | 23.11 Mn |
| Sep 30, 2016 | 22.69 Mn |
| Jun 30, 2016 | 25.59 Mn |
| Mar 31, 2016 | 32.81 Mn |
| Dec 31, 2015 | 40.34 Mn |
| Sep 30, 2015 | 42.73 Mn |
| Jun 30, 2015 | 47.16 Mn |
| Mar 31, 2015 | 53.50 Mn |
| Dec 31, 2014 | 25.84 Mn |
| Sep 30, 2014 | 16.31 Mn |
| Jun 30, 2014 | 16.64 Mn |
| Mar 31, 2014 | 14.89 Mn |
| Dec 31, 2013 | 17.73 Mn |
| Sep 30, 2013 | 16.06 Mn |
| Jun 30, 2013 | 16.54 Mn |
| Mar 31, 2013 | 17.54 Mn |
| Dec 31, 2012 | 20.85 Mn |
| Sep 30, 2012 | 19.41 Mn |
| Jun 30, 2012 | 18.50 Mn |
| Mar 31, 2012 | 17.22 Mn |
| Dec 31, 2011 | 20.84 Mn |
| Sep 30, 2011 | 17.78 Mn |
| Jun 30, 2011 | 17.05 Mn |
| Dec 31, 2010 | 20.43 Mn |